Slingshot Insights | Pfe Overview

PFE Overview

Upcoming Projects (PFE)

Evaluating the Phase 3 VERITAC-2 Trial Results for Vepdegestrant (ARV-471) in ER+/HER2- Breast Cancer from Arvinas and Pfizer
Tickers: ARVN, PFE
Execute By: Aug 31, 2025

Executed Projects (PFE)

A Second Opinion: Looking at the potential of Monte Rosa's Molecular Glue Degrader, MRT-2359, for the treatment of Prostate Cancer
Tickers: GLUE, ALPMF, PFE, JNJ, AMGN, NVS
Executed On: May 06, 2025 at 03:00 PM EDT
Looking at the potential of Monte Rosa's Molecular Glue Degrader, MRT-2359, for the treatment of Prostate Cancer
Tickers: GLUE, ALPMF, PFE, JNJ, AMGN, NVS
Executed On: May 02, 2025 at 01:15 PM EDT
A second look: Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM)
Tickers: ALNY, BBIO, PFE
Executed On: Apr 16, 2025 at 12:00 PM EDT
Looking at Vaxcyte's Phase 2 Topline Results for their VAX-24 Pneumococcal Conjugate Vaccine
Tickers: PCVX, MRK, PFE
Executed On: Apr 03, 2025 at 02:00 PM EDT
Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM)
Tickers: ALNY, BBIO, PFE
Executed On: Apr 01, 2025 at 03:00 PM EDT
Two Week Delay: Survey on ATTR-CM and BBIO-ALNY-PFE Market Dynamic February 2025
Tickers: ALNY, BBIO, PFE
Executed On: Mar 19, 2025 at 09:41 AM EDT
Future Trends in Obesity Management: Perceptions of Oral GLP-1s Orforglipron & Danuglipron
Tickers: PFE, LLY
Executed On: Mar 13, 2025 at 04:00 PM EDT
Discussing Pfizer's Phase 3 results for BRAFTOVI in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
Ticker: PFE
Executed On: Feb 28, 2025 at 10:00 AM EST
A look at the topline results from the Phase 3 CREST trial of Pfizer's sasanlimab in combination with BCG for patients with high-risk non-muscle invasive bladder cancer.
Ticker: PFE
Executed On: Feb 12, 2025 at 03:00 PM EST
Reviewing the recent decision by Pfizer to remove OXBRYTA (voxelotor) for sickle cell disease from the market.
Tickers: PFE, FULC
Executed On: Nov 12, 2024 at 04:45 PM EST
Discussing the treatment landscape for ROS1 NSCLC and the potential of taletrectinib
Tickers: NUVB, NUVL, BMY, PFE
Executed On: Sep 24, 2024 at 11:00 AM EDT
A second look: Discussing the treatment landscape for cervical cancer
Tickers: MRK, PFE
Executed On: Sep 18, 2024 at 04:00 PM EDT
Discussing the treatment landscape for cervical cancer
Tickers: MRK, PFE
Executed On: Sep 10, 2024 at 12:00 PM EDT
Discussing the potential of Vaxcyte's VAX-31 and VAX-24, pneumococcal conjugate vaccine (PCV) candidates designed to prevent invasive pneumococcal disease (IPD)
Tickers: PCVX, MRK, PFE
Executed On: Sep 05, 2024 at 03:30 PM EDT
Looking at the FDA Approval of the Neffy Spray (intranasal ephinephrine) from ARS Pharmaceuticals for anaphylactic shock
Tickers: SPRY, PFE, AQST
Executed On: Aug 15, 2024 at 04:45 PM EDT
A Second Look: Discussing the role of the PRC2/EZH2/EED pathway in prostate cancer
Tickers: ORIC, EPIX, PFE
Executed On: Jul 26, 2024 at 12:30 PM EDT
Discussing the role of the PRC2/EZH2/EED pathway in prostate cancer
Tickers: ORIC, EPIX, PFE
Executed On: Jul 12, 2024 at 10:00 AM EDT
Discussing highlights from ESMO in breast cancer: Pfizer's CDK4-selective inhibitor PF-07220060, Arvinas/Pfizer Vepdegestrant/palbociclib combo & Olema's palazestrant/ribociclib combo
Tickers: PFE, ARVN, OLMA
Executed On: Jun 10, 2024 at 09:00 AM EDT
Discussing new therapies for the treatment of sickle cell disease with a hematologist.
Tickers: AGIO, PFE
Executed On: Apr 02, 2024 at 10:00 AM EDT
A Second Look: A physician's impression of the Modius sleep device, a non-invasive insomnia-treating device from Neurovalens.
Tickers: NEUROVALENS, RHHBF, PFE
Executed On: Nov 13, 2023 at 03:00 PM EST
A physician's impression of the Modius sleep device, a non-invasive insomnia-treating device from Neurovalens.
Tickers: NEUROVALENS, RHHBF, PFE
Executed On: Nov 10, 2023 at 04:00 PM EST
An updated look at the results from the ATTRibute-CM trial of Acoramidis in patients with transthyretin amyloid cardiomyopathy
Tickers: BBIO, PFE, ALNY
Executed On: Sep 06, 2023 at 10:30 AM EDT
A Second Look: Discussing the FDA approval of the Revi System, a tibial nerve stimulation system developed by BlueWind Medical for overactive bladder
Tickers: BLUEWIND MEDICAL, ALPMY, MDT, PFE
Executed On: Aug 25, 2023 at 04:00 PM EDT
Discussing the FDA approval of the Revi System, a tibial nerve stimulation system developed by BlueWind Medical for overactive bladder
Tickers: BLUEWIND MEDICAL, MDT, PFE, ALPMF
Executed On: Aug 24, 2023 at 09:00 AM EDT
Discussing the ATTRibute Part B results on Acoramidis for patients with ATTR cardiomyopathy.
Tickers: BBIO, PFE, ALNY
Executed On: Jul 20, 2023 at 09:00 AM EDT
A Third View: Discussing acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 12, 2023 at 01:00 PM EDT
A Second View: A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 11, 2023 at 01:30 PM EDT
A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Tickers: BBIO, PFE, ALNY
Executed On: Jul 07, 2023 at 01:00 PM EDT
A Second Opinion: Discussing the potential of Pfizer's Marstacimab for the treatment of hemophilia A and B
Ticker: PFE
Executed On: Jun 20, 2023 at 07:00 PM EDT
Discussing the potential of Pfizer's Marstacimab for the treatment of hemophilia A and B
Ticker: PFE
Executed On: Jun 14, 2023 at 02:00 PM EDT
Discussing private and commercial payer reimbursement strategies in the US for Pfizer's Paxlovid with a billing expert who interacts with pharmaceutical companies related to COVID-19 treatment.
Ticker: PFE
Executed On: Apr 21, 2023 at 04:00 PM EDT
Discussing the treatment landscape for alopecia areata with a focus on therapies from Incyte, Concert, Lilly, Pfizer, and Equillium
Tickers: INCY, CNCE, LLY, EQ, PFE
Executed On: Mar 08, 2023 at 01:30 PM EST
An overview of next generation "oral biologics" in treating inflammatory/rheumatological disease
Tickers: IBB, ACRS, DICE, VTYX, IMUX, KYMR, BMY, PTGX, PFE
Executed On: Dec 08, 2022 at 04:00 PM EST
Examining the potential of Valneva and Pfizer's Lyme disease vaccine, VLA15
Tickers: VALN, PFE
Executed On: Nov 01, 2022 at 01:00 PM EDT
Digging into S1P1 modulators as treatment for Ulcerative Colitis with a focus on Zeposia (Ozanimod), Etrasimod, CBP-307 & VTX002
Tickers: BMY, PFE, CNTB, VTYX
Executed On: Sep 23, 2022 at 02:00 PM EDT
Examining the use of Nurtech in migraines and where AXS-07 could fit in if approved
Tickers: AXSM, BHVN, PFE
Executed On: Jul 22, 2022 at 11:00 AM EDT
A look into the proposed mRNA-based vaccine for the prevention of Shingles
Tickers: BNTX, PFE
Executed On: May 24, 2022 at 02:00 PM EDT
A look into the current and developing S1P1 modulators as treatment for Ulcerative Colitis
Tickers: PFE, BMY, CNTB, VTYX
Executed On: Apr 22, 2022 at 01:00 PM EDT
A Second Look: Discussing the potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 24, 2022 at 12:00 PM EST
A look at potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 18, 2022 at 01:00 PM EST
A Second View: Discussing the Pneumococcal vaccine market and where a new vaccine could potentially fit in
Tickers: PFE, PCVX, GSK, MRK, Affinivax, ALPMY
Executed On: Jan 07, 2022 at 10:00 AM EST

Expired Projects (PFE)

Discussing Pfizer’s respiratory syncytial virus vaccine, Abrysvo
Ticker: PFE
Execute By: May 31, 2023
Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Tickers: CNCE, LLY, PFE, INCY
Execute By: Jun 23, 2022
Exploring the recent hemophilia A - SB-525 gene therapy data from Sangamo
Tickers: SGMO, PFE
Execute By: Aug 30, 2019
Evaluating the Chances of Approval and Market Potential of Ariad's Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Before PDUFA of April 29th
Tickers: ARIA, TKPYY, PFE, NVS, RHHBY, Genentech
Execute By: Apr 28, 2017
Discussing the Effectiveness and Market Potential of Pfizer's (PFE) Crisaborole in Atopic Dermatitis After January 7th PDUFA Date
Ticker: PFE
Execute By: Feb 01, 2017
Electroporation Expert Interview: An Overview and its Pharmaceutical Potential
Tickers: INO, PFE, RHHBY, ROLL
Execute By: Nov 02, 2016
Included with Membership

Upcoming & Overdue Catalysts (PFE)

ARV-471 Phase 3 trial
Tickers: ARVN, PFE, OLMA
Future Window: Oct 01, 2023 - Dec 31, 2024
Overdue

Occurred Catalysts (PFE)

Arvinas (ARVN) & Pfizer (PFE) announce update on Phase 1 dose escalation data of ARV-471 in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Tickers: ARVN, PFE
Occurred on: Dec 10, 2021
Pfizer/BioNTech's BNT162b2 vaccine against SARS-CoV-2 U.S. EUA application expected this month
Tickers: PFE, BNTX
Occurred on: Nov 20, 2020
Interim Analysis Results from Pfizer's (PFE) Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer
Ticker: PFE
Occurred on: Sep 30, 2019
Pfizer's (PFE) Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
Ticker: PFE
Occurred on: Aug 27, 2018
U.S. FDA Approves Pfizer’s (PFE) Biosimilar NIVESTYM (filgrastim-aafi)
Ticker: PFE
Occurred on: Jul 18, 2018
Pfizer (PFE) And Lilly (LLY) Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab at 16-weeks For The Treatment Of Osteoarthritis (OA) Pain
Tickers: PFE, LLY
Occurred on: Jul 18, 2018
Pfizer (PFE) initiates a Phase 3 open-label lead-in study evaluating current factor IX prophylaxis replacement therapy in the usual care setting for patients with hemophilia B
Ticker: PFE
Occurred on: Jul 16, 2018
Advisory Committee Meeting for Pfizer's(PFE) Staphylococcus aureus vaccine for pre-surgical prophylaxis expected November 7 2017
Ticker: PFE
Occurred on: Nov 07, 2017
U.S Department of Justice Issues Grand Jury Subpoenas to Pfizer (PFE), ICUI, & BAX as Part of an Antitrust Investigation into the IV Saline Solution Market
Tickers: PFE, BAX, ICUI
Occurred on: Apr 19, 2017
PDUFA Date of April 2017 for Pfizer's (PFE) Supplemental New Drug Application (sNDA) for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Ticker: PFE
Occurred on: Apr 03, 2017
Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Present New Analyses of Eliquis (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session taking place March 17-19
Tickers: BMY, PFE
Occurred on: Mar 17, 2017
Pfizer's' (PFE) Xeljanz Approved in China for Treatment of Adults With Moderate-to-Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response or are Intolerant of Methotrexate (MTX)
Ticker: PFE
Occurred on: Mar 15, 2017
Pfizer (PFE) Launches Zavicefta in the UK and Germany as a Combination Antibiotic to Treat Gram-Negative Bacterial Infections Requiring Hospitalization
Ticker: PFE
Occurred on: Mar 14, 2017
Merck (MRK) and Pfizer (PFE) Plan to Submit NDA By End of 2016 for Ertugliflozin in Combination with Januvia (sitagliptin) and Metformin in Treatment of Type 2 Diabetes
Tickers: MRK, PFE
Occurred on: Mar 06, 2017
European Commission (EC) Approves Roche's (RHHBY) Alecensa for Adult Patients with Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer Who Have Taken Pfizer's (PFE) Xalkori (Crizotinib)
Tickers: RHHBY, PFE
Occurred on: Feb 21, 2017
Pfizer (PFE) Presents Phase 3b/4 ORAL Strategy Data Evaluating XELJANZ + Methotrexate (MTX) Compared to AbbVie's (ABBV) Humira in Moderate-to-Severe Rheumatoid Arthritis (RA)
Ticker: PFE
Occurred on: Feb 16, 2017
Pfizer (PFE) AnnouncesTop-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection
Ticker: PFE
Occurred on: Jan 26, 2017
Pfizer's (PFE) Supplemental New Drug Application for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative (ER+, HER2-) Metastatic Breast Cancer Accepted for FDA Review
Ticker: PFE
Occurred on: Dec 21, 2016
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016
PDUFA Date of January 7, 2017 for Pfizer's (PFE) Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis
Ticker: PFE
Occurred on: Dec 14, 2016
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Ticker: PFE
Occurred on: Nov 29, 2016
PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer
Ticker: PFE
Occurred on: Nov 16, 2016
Pfizer (PFE) Expects Decision From European Medicines Agency on IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer By End of November
Ticker: PFE
Occurred on: Nov 10, 2016
Pfizer's (PFE) Prevenar Approved in China for the Prevention of Invasive Pneumococcal Disease in Infants and Children Aged Six Weeks to Fifteen Months
Ticker: PFE
Occurred on: Nov 02, 2016
Pfizer (PFE) Terminates Development of Cholesterol Lowering Candidate Bococizumab
Ticker: PFE
Occurred on: Nov 01, 2016
Esperion Therapeutics (ESPR) Announces Phase 2 Data Evaluating Bempedoic Acid Added to Atorvastatin in Hypercholesterolemia
Tickers: ESPR, PFE
Occurred on: Oct 13, 2016
Pfizer (PFE) Presents Phase 3 S-TRAC Results Evaluating Sutent (sunitinib) in Patients with Renal Cell Carcinoma
Ticker: PFE
Occurred on: Oct 10, 2016
2nd Presidential Debate between Donald Trump and Hillary Clinton at Washington University in St. Louis, Missouri from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, MYL, Turing Pharmaceuticals, GILD
Occurred on: Oct 09, 2016
First Presidential debate between Donald Trump and Hillary Clinton at Hofstra University, New York, from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, GILD, MYL
Occurred on: Sep 26, 2016
Pfizer's (PFE) IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer Recommended for Approval by European Ad Comm
Ticker: PFE
Occurred on: Sep 16, 2016
Pfizer (PFE) Announces Phase 3 REFLECTIONS B537-02 Data Evaluating Remicade Biosimilar in Rheumatoid Arthritis
Tickers: PFE, NVS
Occurred on: Sep 16, 2016
Merck (MRK) and Pfizer (PFE) Announce Phase 3 Results for Type 2 Diabetes Candidate Ertugliflozin
Tickers: MRK, PFE
Occurred on: Sep 15, 2016
Aerie Pharmaceuticals (AERI) Releases Positive Phase 3 Data on Roclatan for Lowering Intraocular Pressure (IOP) in Patients with Glaucoma or Ocular Hypertension
Tickers: AERI, PFE
Occurred on: Sep 14, 2016
FDA Approves TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
Ticker: PFE
Occurred on: Aug 19, 2016
Pfizer reaches $486M settlement of nationwide litigation relating to its Celebrex and Bextra pain-relieving drugs of Celebrex, Bextra pain-relieving drugs
Ticker: PFE
Occurred on: Aug 02, 2016
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
Ticker: PFE
Occurred on: Jul 13, 2016
Pfizer Receives FDA Approval for Prevnar 13 in Adults Age 18 Through 49
Ticker: PFE
Occurred on: Jul 12, 2016
BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer
Tickers: BIND, PFE
Occurred on: Jul 01, 2016
Pfizer Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase 3 Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia
Ticker: PFE
Occurred on: Jun 12, 2016
Merck And Pfizer Announce Two Pivotal Phase 3 Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes
Tickers: PFE, MRK
Occurred on: Jun 11, 2016
Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis
Ticker: PFE
Occurred on: Jun 07, 2016
The First Phase 3 trial for Plecanatide in IBS-C read out
Tickers: SGYP, PFE, AGN, VRX, IRWD
Occurred on: May 22, 2016
Phase 3 Studies of Tanezumab for Chronic Pain Resume After Partial Clinical Hold
Tickers: PFE, LLY
Occurred on: Mar 23, 2016
Pfizer Announces FDA Approval of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
Ticker: PFE
Occurred on: Feb 24, 2016
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015
GlycoMimetics (GLYC) and Pfizer (PFE) Initiate Phase 1 Trial Evaluating Subcutaneous Administration of Rivipansel in Vaso-Occlusive Crisis in Sickle Cell Disease
Tickers: GLYC, PFE
Occurred on: Oct 29, 2015
Allergan (AGN) Launches Over-the-counter Artificial Tear REFRESH OPTIVE Gel Drops for Dry Eye Symptoms
Tickers: AGN, PFE
Occurred on: Oct 21, 2015
Allergan (AGN) Issues Statement Regarding Specialty Pharmacy Utilization and Resumes Trading
Tickers: AGN, PFE, VRX
Occurred on: Oct 21, 2015
Allergan (AGN) Completes Acquisition of AqueSys and XEN45 for $300 Million
Tickers: AGN, PFE
Occurred on: Oct 19, 2015
FDA Grants Pfizer's (PFE) Inotuzumab Ozogamicin Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia
Ticker: PFE
Occurred on: Oct 19, 2015
Allergan (AGN) Presents Paper Titled "Facial Treatment Preferences in Aesthetically-Oriented Men" at American Society of Dermatologic Surgery Meeting
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015
Allergan (AGN) Presents Data From Harmony Study on Combined Facial Aesthetic Treatment With Botox, Dermal Fillers, and Bimatoprost
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015
FDA Sends Pfizer (PFE) Complete Response Letter Rejecting Oral XELJANZ Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis
Ticker: PFE
Occurred on: Oct 14, 2015

Strategic Initiatives (PFE)

Myovant Sciences (MYOV) and Pfizer (PFE) Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Tickers: MYOV, PFE
Announcement Date: Dec 28, 2020
Pfizer (PFE) spin off Upjohn Business merges with Mylan N.V. (MYL), forming Viatris Inc. (VTRS)
Tickers: PFE, MYL
Announcement Date: Nov 16, 2020
Pfizer (PFE) is set to purchase 5,000,000 of Homology’s (FIXX) common stock at a price of $12.00 per share
Tickers: FIXX, PFE
Announcement Date: Nov 09, 2020
Antares Pharma (ATRS) Enters into a Development Agreement with Pfizer (PFE) to develop a combination drug device rescue pen
Tickers: ATRS, PFE
Announcement Date: Aug 06, 2018
ICU Medical (ICUI) Announces $1B Cash & Stock Purchase of Pfizer's (PFE) Hospira Infusion Therapy Unit
Tickers: ICUI, PFE
Announcement Date: Oct 06, 2016
Pfizer (PFE) Decides Not to Split Company, Will Operate as One Company With Two Distinct and Complementary Businesses to Maximize Future Value Creation
Ticker: PFE
Announcement Date: Sep 26, 2016
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca
Tickers: PFE, AZN
Announcement Date: Aug 24, 2016
Pfizer near $14 billion acquisition of Medivation
Tickers: PFE, MDVN
Announcement Date: Aug 21, 2016
BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets
Tickers: BIND, PFE
Announcement Date: Jul 26, 2016
Pfizer Completes Acquisition of Anacor
Tickers: PFE, ANAC
Announcement Date: Jun 23, 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Tickers: BMY, PFE, PTLA
Announcement Date: Feb 02, 2016